血浆C反应蛋白与癌症风险：一项来自希腊的前瞻性研究。

Plasma C-reactive protein and risk of cancer: a prospective study from Greece.

作者信息

Trichopoulos Dimitrios, Psaltopoulou Theodora, Orfanos Philippos, Trichopoulou Antonia, Boffetta Paolo

机构信息

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.

出版信息

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):381-4. doi: 10.1158/1055-9965.EPI-05-0626.

DOI:10.1158/1055-9965.EPI-05-0626

PMID:16492932

Abstract

BACKGROUND

Inflammation is an important component of carcinogenesis but little research has been conducted on whether inflammation markers can be predictive of cancer risk in humans.

METHODS

We analyzed C-reactive protein (CRP), a marker of inflammation, in plasma samples of 496 cases of cancer and 996 controls selected among participants in a prospective study from Greece.

RESULTS

Plasma CRP level was higher in cancer cases than controls (odds ratio for increase in CRP level of 3.2 mg/L, 1.20; 95% confidence interval, 1.10-1.32): The corresponding odds ratio after exclusion of the first year of follow-up and of individuals with CRP level above 20 mg/L was 1.32 (95% confidence interval, 1.15-1.52). Although based on small number of cases, the association between elevated plasma CRP level and risk was stronger for cancers of the liver, lung, skin, kidney, and bladder, as well as for lymphoma and leukemia than for other neoplasms.

CONCLUSIONS

Our results confirm the important role of inflammation in human cancer and suggest that plasma CRP level is a potential marker of increased cancer risk.

摘要

背景

炎症是致癌过程的一个重要组成部分，但关于炎症标志物是否能预测人类癌症风险的研究较少。

方法

我们分析了来自希腊一项前瞻性研究参与者中的496例癌症患者和996例对照者血浆样本中的炎症标志物C反应蛋白（CRP）。

结果

癌症患者的血浆CRP水平高于对照组（CRP水平每升高3.2 mg/L的比值比为1.20；95%置信区间为1.10 - 1.32）：排除随访第一年及CRP水平高于20 mg/L的个体后，相应的比值比为1.32（95%置信区间为1.15 - 1.52）。尽管病例数量较少，但与其他肿瘤相比，血浆CRP水平升高与肝癌、肺癌、皮肤癌、肾癌、膀胱癌以及淋巴瘤和白血病风险之间的关联更强。